Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel

American Heart Journal

Volumn 162, Issue 4, 2011, Pages 733-739

  Alexopoulos, Dimitrios ^a   Xanthopoulou, Ioanna ^a   Davlouros, Periklis ^a   Plakomyti, Theodora Eleni ^a   Panagiotou, Aggeliki ^a   Mavronasiou, Eleni ^a   Hahalis, George ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PRASUGREL; PROTON PUMP INHIBITOR; THROMBOCYTE SLOWING FACTOR;

AGED; ARTICLE; BLEEDING; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONG TERM CARE; MAINTENANCE THERAPY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SMOKING; THROMBOCYTE FUNCTION; TREATMENT DURATION;

AGED; CHRONIC DISEASE; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SINGLE-BLIND METHOD; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 80053630737     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.07.026     Document Type: Article

References (26)

1. F.G. Kushner, M. Hand, and S.C. Smith 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
2. W. Wijns, P. Kolh, and N. Danchin Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 31 2010 2501 2555
3. D.L. Bhatt, M.D. Flather, and W. Hacke Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial J Am Coll Cardiol 49 2007 1982 1988 (Pubitemid 46694290)
4. P.A. Gurbel, K.P. Bliden, and B.L. Hiatt Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913 (Pubitemid 36736631)
5. G. Patti, A. Nusca, and F. Mangiacapra Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study J Am Coll Cardiol 52 2008 1128 1133
6. R. Marcucci, A.M. Gori, and R. Paniccia Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
7. T. Cuisset, M. Hamilos, and J. Sarma Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris Am J Cardiol 101 2008 1700 1703
8. M.J. Price, K.R. Nayak, and C.M. Barker Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention Am J Cardiol 103 2009 1339 1343
9. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 54 2005 2430 2435 (Pubitemid 41134272)
10. D.J. Angiolillo, E. Bernardo, and M. Sabate Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 2007 1541 1547 (Pubitemid 47532327)
11. D.J. Angiolillo, S.B. Shoemaker, and B. Desai Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 2007 708 716 (Pubitemid 46294761)
12. D. Trenk, W. Hochholzer, and B. Muller Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement EuroIntervention 4 2008 214 221
13. B. Aleil, L. Jacquemin, and F. De Poli Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study JACC Cardiovasc Interv 1 2008 631 638
14. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
15. D. Alexopoulos, G. Dimitropoulos, and P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel the importance of CYP2C192 genotyping JACC Cardiovasc Interv 4 2011 403 410
16. P.A. Gurbel, K.P. Bliden, and K. Butler Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
17. K.P. Bliden, J. DiChiara, and U.S. Tantry Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 49 2007 657 666 (Pubitemid 46205039)
18. A. Kastrati, N. von Beckerath, and A. Joost Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy Circulation 110 2004 1916 1919 (Pubitemid 39331901)
19. L. Wallentin, C. Varenhorst, and S. James Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
20. D.J. Angiolillo, J.F. Saucedo, and R. Deraad Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study J Am Coll Cardiol 56 2010 1017 1023
21. S.D. Wiviott, D. Trenk, and A.L. Frelinger Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 116 2007 2923 2932 (Pubitemid 350291199)
22. G. Montalescot, G. Sideris, and R. Cohen Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study Thromb Haemost 103 2010 213 223
23. D.J. Angiolillo, J.J. Badimon, and J.F. Saucedo A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial Eur Heart J 32 2011 838 846
24. D.R. Holmes Jr., G.J. Dehmer, and S. Kaul ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Circulation 122 2010 537 557
25. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
26. H. Neubauer, A.F. Kaiser, and H.G. Endres Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy BMC Med 9 2011 3